Palavras-chave
líquen plano oral, apoptose, proliferação
Como Citar
Inmunoexpresión de biomarcadores Bax, Bcl-2, CD138, H3, Ki-67, MCM3 y p53 en liquen plano oral. (2019). Odontoestomatología, 21(34), 16-26. https://doi.org/10.22592/ode2019n34a3
Resumo
O objetivo deste trabalho foi determinar a expressão de vários biomarcadores moleculares no líquen plano oral para ajudar a compreender seu comportamento biológico. Materiais e métodos: Foi realizado um estudo imunohistoquímico em 40 casos de líquen plano oral contra BAX, BCL-2, CD-138, Histona 3, Ki-67, MCM3 e p53, na área de Patologia Molecular Estomatológica da Faculdade de Odontologia , UDELAR, Uruguai. Resultados: Observou-se aumento da expressão de BAX em contraste com BCL-2, sugerindo um comportamento proapoptótico, apoiado por sua vez pela ausência da expressão de p53. A expressão de marcadores de proliferação celular foi observada em todo o tecido da lesão, sugerindo alterações na proliferação. CD-138 foi expressado de maneira intensa e uniforme, determinando uma baixa alteração das junções intercelulares para esses casos. Conclusões: A alteração na expressão das proteínas estudadas sugere um distúrbio nos mecanismos proliferativos e apoptóticos, os quais estão associados a um comportamento patológico da mucosa oral.
Referências
1. Cerero-Lapiedra R. Malignización del liquen plano oral. Av. Odontoestomatol 2008; 24 (1): 97-103.
2. Rodríguez Acar M, Carbajal Pruenda P. Liquen plano. Revisión de la literatura. Rev Cent Dermatol Pascua. 2006; 15 (3): 203-208. 3. Bermejo F, López-Jornet P. Liquen plano oral. Naturaleza, aspectos clínicos y tratamiento. RCOE. 2004; 9 (3): 395-408. 4. Warnakulasuriya S, Johnson NW, Van Der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007; 36: 575-580. 5. Cawson R, Odell E. Fundamentos de medicinal y patología oral. 9ª ed. Barcelona: Elsavier; 2017. 262-267p. 6. Blanco Carrión A, Otero Rey E, Peñamaría Mallón M, Diniz Freitas M. Diagnóstico del liquen plano oral. Av Odontoestomatol 2008; 24 (1): 11-31. 7. Sapp J.P. Eversole L.R. Wysolki G.W. Patología Oral y Maxilofacial. 2ª ed. Madrid: Elsavier; 2004. 250-253p. 8. Bascones-Ilundain C, González Moles MA, Campo-Trapero J, Bascones-Martínez A. Liquen plano oral (II). Mecanismos apoptóticos y posible malignización. Av. Odontoestomatol 2006; 22 (1): 21-31. 9. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin. Dermatol. 2010; 28(1) :100-108. 10. Gorsky M, Epstein JB, Hasson-Kanfi H, Kaufman E. Smoking habits among patients diagnosed with oral lichen planus. Tobacco Induced Diseases. 2004; 2(2): 103-8. 11. Iijima W, Ohtani H, Nakayama T, Sugawara Y, Sato E, Nagura H, Yoshie O, Sasano T. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am. J. Pathol. 2003; 163(1): 261- 268. 12. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100(1): 40-51. 13. Sreenivasan V . The malignant potential of oral lichen planus - confusion galore. OOOO Journal.2013; 115(3): 415. 14. Fitzpatrick S, Hirsch S, Gordon S. The malignant od oral lichen planus and oral lichenoid lesions. A systematic review. JADA. 2014; 145 (1): 45-56. 15. Shivhare P, Gupta A, Yadav M, Konidena A, Shankarnarayan L. Evaluation of different diagnostic criteria of diseases manifesting the oral cavity – A review. Part-1. JOBCR. 2016; 6(2): 135-141. 16. Fernández-González F, Vázquez R, Reboiras D, Gándara P, García A, Gándara JM. Histopathological findings in oral lichen planus and their correlation with the clinical manifestations. Med. Oral Patol. Oral Cir. Bucal. 2011; 16(5): 641-646. 17. Druilhe A, Benoit W, Tsicopoulos A, Lapa JR, Tillie-Leoblond I, Tonnel A, Pretolani M. Apoptosis, proliferation, and expression of bcl2, Fas and Fas-ligand in bronchial biopsies from asthmatics. AJRCCM. 1998; 19(5): 747-57. 18. Renault T, Dejean L, Manon Stephen. A brewing understanding of the regulation of Bax función by Bcl-xL and Bcl-2. Mechanisms of Agening and Development. 2017; 161: 201210. 19. Bose P, Klimowicz AC, Kornaga E, Petrillo SK, Matthews TW, Chandarana S, Magliocco AM, Brockton NT, Dort JC. Bax expression measured by AQUanalysis is an independent prognostic marker in oral squamous cell carcinoma. BMC Cancer. 2012; 12: 332-343. 20. Sagari S, Sanadhya S, Doddamani M, Rajput R. Molecular markers in oral lichen planus: A systematic review. JOMFP. 2016; 20(1): 115121. 21. Suri C. The immunohistochemical evaluation of the expression of BCL-2 in different histological grades of squamous cell carcinoma. J Clin Diagn Res. 2009; 3:1891-9. 22. Amarante GP, Green DR. The regulation of apoptotic cell death. Braz J Med Biol Res. 1999; 32(9): 1053-1061. 23. Pruneri G, Pignataro L, Carboni N, Ronchetti D, Cesana B, Ottaviani A, Neri A, Buffa R. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int. J. Cancer. 1998; 79: 263-268.
24. Bascones-Ilundain C, González Moles MA, Campo-Trapero J, Bascones-Martínez A. Liquen plano oral (II). Mecanismos apoptóticos y posible malignización. Av Odontoestomatol. 2006; 22(1): 21-27. 25. Shailaja G, Kumar JV, Baghirath PV, Kumar U, Ashalata G, Krishna AB. Estimation of malignant transformation rate in cases of oral epithelial dysplasia and lichen planus using immunohistochemical expression of Ki-67, p53, BCL-2, and BAX markers. DRJ. 2015; 12(3): 235-242. 26. Bogdan C, Kazuhiko O, Ken Y, Seban T, Tomoko T, Toshio I. Role of p53-mediated apoptotic pathway in oral lichen planus: Relationship among pro-apoptotic, anti-apoptotic, and keratinocytic markers. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 2014; 26(2): 221-227. 27. Tampa M, Caruntu C, Mitran M, Mitran C, Sarbu I, Rusu LC, Matei C, Constantin C, Neagu M, Georgescu SR. Markers of Oral Lichen Planus Malignant Transformation. Dis Markers. 2018 28. Humayun S, Prasad VR. Expression of p53 protein and ki-67 antigen in oral premalignant lesions and oral squamous cell carcinomas: An immunohistochemical study. Natl J Maxillofac Surg. 2011; 2(1): 38-46. 29. Ravi D, Nalinakumari KR, Rajaram RS, Nair MK, Pillai MR. Expresion of programmed cell death regulatory p53 and bcl-2 proteins in oral lesions. Cancer Letters. 1996; 105 (2): 139- 146. 30. Basheer S, Shameena PM, Shuda S, Varma S, Vidyanath S, Varekar A. Expression of survivin and p53 in oral lichen planus, lichenoid reaction and lichenoid dysplasia: An immunohistochemical study. JOMFP. 2017;21 (3): 456-457. 31. Manal M, Zyada PhD, Hala E, Fikry PhD. Immunohistochemical study of syndecan-1 down- regulation and the expression of P53 protein in oral lichen planus: a clinicopathologic correlation with hepatitis C infection in the Egyptian population. Annals of Diagnostic Pathology. 2010; 14(3): 153-161. 32. Rezazadeh F, Ebrahimi R, Andisheh-Tabdir A, Ashraf M, Khademi B. Evaluation of the Ki- 67 and MCM3 Expression in Cytologic Smear of Oral Squamous Cell Carcinoma. J Dent (Shiraz). 2017; 18(3): 207-211. 33. Gan N, Du Y, Zhang W, Zhou J. Increase of Mcm3 and Mcm4 expression in cervical squamous cell carcinomas. Eur. J. Gynaeco. Oncol. 2010; 31: 291–294. 34. Ha SA, Shin SM, Namkoong H, Lee H, Cho GW, Hur SY, Kim TE, Kim JW. Cancerassociated expression of minichromos-ome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. CCR. 2004; 10: 8386-8395. 35. Manchano A, Bologna R, Toussaint S, Vega M, González J. Expression of E-cadherin, 36. syndecan 1, Ki-67, and maintenance minichromosome 3 in tissue lesions of actinic prurigo obtained by incisional biopsy. Indian Journal of pathology and microbiology. 2018; 61(2): 225- 227. 37. Bhasin M, Reinherz EL, Reche PA. Recognition and classification of histones using support
vector machine. Journal of Computational Biology. 2016; 13(1): 102–120. 38. Rosenfeld JA, Wang Z, Schones DE, Zhao K, DeSalle R, Zhang MQ. Determination of enriched histone modifications in non-genic portions of the human genome. BMC Genomics. 2009; 10: 143-154. 39. Carey DJ, Stahl RC, Tucker B, Bendt KA, Cizmeci-Smith G. Aggregation-induced association of syndecan - 1 white microfilaments mediated by the cytoplasmic domain. Exp Cell Res. 1994; 214: 12-21. 40. Soukka T, Pohjola J, Inki P, Happonen RP. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium. J Oral Pathol Med. 2000; 29(7): 308-313. 41. Zink LM, Hake SB. Histone variants: nuclear function and disease. Curr Opin Genet Dev. 2016; 37: 82-89.
2. Rodríguez Acar M, Carbajal Pruenda P. Liquen plano. Revisión de la literatura. Rev Cent Dermatol Pascua. 2006; 15 (3): 203-208. 3. Bermejo F, López-Jornet P. Liquen plano oral. Naturaleza, aspectos clínicos y tratamiento. RCOE. 2004; 9 (3): 395-408. 4. Warnakulasuriya S, Johnson NW, Van Der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007; 36: 575-580. 5. Cawson R, Odell E. Fundamentos de medicinal y patología oral. 9ª ed. Barcelona: Elsavier; 2017. 262-267p. 6. Blanco Carrión A, Otero Rey E, Peñamaría Mallón M, Diniz Freitas M. Diagnóstico del liquen plano oral. Av Odontoestomatol 2008; 24 (1): 11-31. 7. Sapp J.P. Eversole L.R. Wysolki G.W. Patología Oral y Maxilofacial. 2ª ed. Madrid: Elsavier; 2004. 250-253p. 8. Bascones-Ilundain C, González Moles MA, Campo-Trapero J, Bascones-Martínez A. Liquen plano oral (II). Mecanismos apoptóticos y posible malignización. Av. Odontoestomatol 2006; 22 (1): 21-31. 9. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin. Dermatol. 2010; 28(1) :100-108. 10. Gorsky M, Epstein JB, Hasson-Kanfi H, Kaufman E. Smoking habits among patients diagnosed with oral lichen planus. Tobacco Induced Diseases. 2004; 2(2): 103-8. 11. Iijima W, Ohtani H, Nakayama T, Sugawara Y, Sato E, Nagura H, Yoshie O, Sasano T. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am. J. Pathol. 2003; 163(1): 261- 268. 12. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100(1): 40-51. 13. Sreenivasan V . The malignant potential of oral lichen planus - confusion galore. OOOO Journal.2013; 115(3): 415. 14. Fitzpatrick S, Hirsch S, Gordon S. The malignant od oral lichen planus and oral lichenoid lesions. A systematic review. JADA. 2014; 145 (1): 45-56. 15. Shivhare P, Gupta A, Yadav M, Konidena A, Shankarnarayan L. Evaluation of different diagnostic criteria of diseases manifesting the oral cavity – A review. Part-1. JOBCR. 2016; 6(2): 135-141. 16. Fernández-González F, Vázquez R, Reboiras D, Gándara P, García A, Gándara JM. Histopathological findings in oral lichen planus and their correlation with the clinical manifestations. Med. Oral Patol. Oral Cir. Bucal. 2011; 16(5): 641-646. 17. Druilhe A, Benoit W, Tsicopoulos A, Lapa JR, Tillie-Leoblond I, Tonnel A, Pretolani M. Apoptosis, proliferation, and expression of bcl2, Fas and Fas-ligand in bronchial biopsies from asthmatics. AJRCCM. 1998; 19(5): 747-57. 18. Renault T, Dejean L, Manon Stephen. A brewing understanding of the regulation of Bax función by Bcl-xL and Bcl-2. Mechanisms of Agening and Development. 2017; 161: 201210. 19. Bose P, Klimowicz AC, Kornaga E, Petrillo SK, Matthews TW, Chandarana S, Magliocco AM, Brockton NT, Dort JC. Bax expression measured by AQUanalysis is an independent prognostic marker in oral squamous cell carcinoma. BMC Cancer. 2012; 12: 332-343. 20. Sagari S, Sanadhya S, Doddamani M, Rajput R. Molecular markers in oral lichen planus: A systematic review. JOMFP. 2016; 20(1): 115121. 21. Suri C. The immunohistochemical evaluation of the expression of BCL-2 in different histological grades of squamous cell carcinoma. J Clin Diagn Res. 2009; 3:1891-9. 22. Amarante GP, Green DR. The regulation of apoptotic cell death. Braz J Med Biol Res. 1999; 32(9): 1053-1061. 23. Pruneri G, Pignataro L, Carboni N, Ronchetti D, Cesana B, Ottaviani A, Neri A, Buffa R. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int. J. Cancer. 1998; 79: 263-268.
24. Bascones-Ilundain C, González Moles MA, Campo-Trapero J, Bascones-Martínez A. Liquen plano oral (II). Mecanismos apoptóticos y posible malignización. Av Odontoestomatol. 2006; 22(1): 21-27. 25. Shailaja G, Kumar JV, Baghirath PV, Kumar U, Ashalata G, Krishna AB. Estimation of malignant transformation rate in cases of oral epithelial dysplasia and lichen planus using immunohistochemical expression of Ki-67, p53, BCL-2, and BAX markers. DRJ. 2015; 12(3): 235-242. 26. Bogdan C, Kazuhiko O, Ken Y, Seban T, Tomoko T, Toshio I. Role of p53-mediated apoptotic pathway in oral lichen planus: Relationship among pro-apoptotic, anti-apoptotic, and keratinocytic markers. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 2014; 26(2): 221-227. 27. Tampa M, Caruntu C, Mitran M, Mitran C, Sarbu I, Rusu LC, Matei C, Constantin C, Neagu M, Georgescu SR. Markers of Oral Lichen Planus Malignant Transformation. Dis Markers. 2018 28. Humayun S, Prasad VR. Expression of p53 protein and ki-67 antigen in oral premalignant lesions and oral squamous cell carcinomas: An immunohistochemical study. Natl J Maxillofac Surg. 2011; 2(1): 38-46. 29. Ravi D, Nalinakumari KR, Rajaram RS, Nair MK, Pillai MR. Expresion of programmed cell death regulatory p53 and bcl-2 proteins in oral lesions. Cancer Letters. 1996; 105 (2): 139- 146. 30. Basheer S, Shameena PM, Shuda S, Varma S, Vidyanath S, Varekar A. Expression of survivin and p53 in oral lichen planus, lichenoid reaction and lichenoid dysplasia: An immunohistochemical study. JOMFP. 2017;21 (3): 456-457. 31. Manal M, Zyada PhD, Hala E, Fikry PhD. Immunohistochemical study of syndecan-1 down- regulation and the expression of P53 protein in oral lichen planus: a clinicopathologic correlation with hepatitis C infection in the Egyptian population. Annals of Diagnostic Pathology. 2010; 14(3): 153-161. 32. Rezazadeh F, Ebrahimi R, Andisheh-Tabdir A, Ashraf M, Khademi B. Evaluation of the Ki- 67 and MCM3 Expression in Cytologic Smear of Oral Squamous Cell Carcinoma. J Dent (Shiraz). 2017; 18(3): 207-211. 33. Gan N, Du Y, Zhang W, Zhou J. Increase of Mcm3 and Mcm4 expression in cervical squamous cell carcinomas. Eur. J. Gynaeco. Oncol. 2010; 31: 291–294. 34. Ha SA, Shin SM, Namkoong H, Lee H, Cho GW, Hur SY, Kim TE, Kim JW. Cancerassociated expression of minichromos-ome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. CCR. 2004; 10: 8386-8395. 35. Manchano A, Bologna R, Toussaint S, Vega M, González J. Expression of E-cadherin, 36. syndecan 1, Ki-67, and maintenance minichromosome 3 in tissue lesions of actinic prurigo obtained by incisional biopsy. Indian Journal of pathology and microbiology. 2018; 61(2): 225- 227. 37. Bhasin M, Reinherz EL, Reche PA. Recognition and classification of histones using support
vector machine. Journal of Computational Biology. 2016; 13(1): 102–120. 38. Rosenfeld JA, Wang Z, Schones DE, Zhao K, DeSalle R, Zhang MQ. Determination of enriched histone modifications in non-genic portions of the human genome. BMC Genomics. 2009; 10: 143-154. 39. Carey DJ, Stahl RC, Tucker B, Bendt KA, Cizmeci-Smith G. Aggregation-induced association of syndecan - 1 white microfilaments mediated by the cytoplasmic domain. Exp Cell Res. 1994; 214: 12-21. 40. Soukka T, Pohjola J, Inki P, Happonen RP. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium. J Oral Pathol Med. 2000; 29(7): 308-313. 41. Zink LM, Hake SB. Histone variants: nuclear function and disease. Curr Opin Genet Dev. 2016; 37: 82-89.